159: Ozempic, Wegovy, and our questions on weight management drugs
Host Rachel Woods talks with researchers Kara Marlatt, Gaby Marmolejos, and Chloe Bakst about the questions healthcare leaders have about the growing demand and accessibility of new weight management drugs and what this could mean for the industry.
Audio is streamed directly from the publisher (aphid.fireside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Demand – and concern – is growing for the newest generation of weight loss drugs. Approved by the FDA to treat type 2 diabetes, drugs like Ozempic and Wegovy have set off a media frenzy as celebrities and the wealthy touted their weight loss benefits. Leaders have a lot of questions about protocol, supply, and coverage of these drugs, and the consequences of patients using them for their unintended purpose. In this episode, host Rachel (Rae) Woods walks through these questions with experts Kara Marlatt, Gaby Marmolejos, and Chloe Bakst and discuss the potential future of weight management in US healthcare.
Links:
- 6 questions providers and health plans need to answer about weight loss drugs
- Are we entering a new era of weight-loss medication?
- Why did WeightWatchers just buy a telehealth platform?
Learn more about Advisory Board Sponsorship opportunities at advisory.com/sponsorship